175 related articles for article (PubMed ID: 15379707)
1. Etoposide: discovery and medicinal chemistry.
Meresse P; Dechaux E; Monneret C; Bertounesque E
Curr Med Chem; 2004 Sep; 11(18):2443-66. PubMed ID: 15379707
[TBL] [Abstract][Full Text] [Related]
2. Structure-based design, synthesis and biological testing of piperazine-linked bis-epipodophyllotoxin etoposide analogs.
Yadav AA; Chee GL; Wu X; Patel D; Yalowich JC; Hasinoff BB
Bioorg Med Chem; 2015 Jul; 23(13):3542-51. PubMed ID: 25922181
[TBL] [Abstract][Full Text] [Related]
3. Antitumor agents. Part 235: Novel 4'-ester etoposide analogues as potent DNA topoisomerase II inhibitors with improved therapeutic potential.
Xiao Z; Vance JR; Bastow KF; Brossi A; Wang HK; Lee KH
Bioorg Med Chem; 2004 Jun; 12(12):3363-9. PubMed ID: 15158805
[TBL] [Abstract][Full Text] [Related]
4. Synthesis and evaluation of etoposide and podophyllotoxin analogs against topoisomerase IIα and HCT-116 cells.
Murphy MB; Kumar P; Bradley AM; Barton CE; Deweese JE; Mercer SL
Bioorg Med Chem; 2020 Nov; 28(22):115773. PubMed ID: 33035756
[TBL] [Abstract][Full Text] [Related]
5. Cytotoxicity and cell death mechanisms induced by the polyamine-vectorized anti-cancer drug F14512 targeting topoisomerase II.
Brel V; Annereau JP; Vispé S; Kruczynski A; Bailly C; Guilbaud N
Biochem Pharmacol; 2011 Dec; 82(12):1843-52. PubMed ID: 21924246
[TBL] [Abstract][Full Text] [Related]
6. Etoposide, topoisomerase II and cancer.
Baldwin EL; Osheroff N
Curr Med Chem Anticancer Agents; 2005 Jul; 5(4):363-72. PubMed ID: 16101488
[TBL] [Abstract][Full Text] [Related]
7. DNA topoisomerase II as the target for the anticancer drug TOP-53: mechanistic basis for drug action.
Byl JA; Cline SD; Utsugi T; Kobunai T; Yamada Y; Osheroff N
Biochemistry; 2001 Jan; 40(3):712-8. PubMed ID: 11170388
[TBL] [Abstract][Full Text] [Related]
8. Human small cell lung cancer NYH cells selected for resistance to the bisdioxopiperazine topoisomerase II catalytic inhibitor ICRF-187 demonstrate a functional R162Q mutation in the Walker A consensus ATP binding domain of the alpha isoform.
Wessel I; Jensen LH; Jensen PB; Falck J; Rose A; Roerth M; Nitiss JL; Sehested M
Cancer Res; 1999 Jul; 59(14):3442-50. PubMed ID: 10416608
[TBL] [Abstract][Full Text] [Related]
9. Antitumor agents. 194. Synthesis and biological evaluations of 4-beta-mono-, -di-, and -trisubstituted aniline-4'-O-demethyl-podophyllotoxin and related compounds with improved pharmacological profiles.
Zhu XK; Guan J; Tachibana Y; Bastow KF; Cho SJ; Cheng HH; Cheng YC; Gurwith M; Lee KH
J Med Chem; 1999 Jul; 42(13):2441-6. PubMed ID: 10395485
[TBL] [Abstract][Full Text] [Related]
10. A two-drug model for etoposide action against human topoisomerase IIalpha.
Bromberg KD; Burgin AB; Osheroff N
J Biol Chem; 2003 Feb; 278(9):7406-12. PubMed ID: 12473657
[TBL] [Abstract][Full Text] [Related]
11. A diazirine-based photoaffinity etoposide probe for labeling topoisomerase II.
Chee GL; Yalowich JC; Bodner A; Wu X; Hasinoff BB
Bioorg Med Chem; 2010 Jan; 18(2):830-8. PubMed ID: 20006518
[TBL] [Abstract][Full Text] [Related]
12. Synthesis and evaluation of novel ellipticines as potential anti-cancer agents.
Deane FM; O'Sullivan EC; Maguire AR; Gilbert J; Sakoff JA; McCluskey A; McCarthy FO
Org Biomol Chem; 2013 Feb; 11(8):1334-44. PubMed ID: 23314103
[TBL] [Abstract][Full Text] [Related]
13. Design, synthesis, and antitumor evaluation of 2,4,6-triaryl pyridines containing chlorophenyl and phenolic moiety.
Thapa P; Karki R; Yun M; Kadayat TM; Lee E; Kwon HB; Na Y; Cho WJ; Kim ND; Jeong BS; Kwon Y; Lee ES
Eur J Med Chem; 2012 Jun; 52():123-36. PubMed ID: 22503656
[TBL] [Abstract][Full Text] [Related]
14. Structural basis of type II topoisomerase inhibition by the anticancer drug etoposide.
Wu CC; Li TK; Farh L; Lin LY; Lin TS; Yu YJ; Yen TJ; Chiang CW; Chan NL
Science; 2011 Jul; 333(6041):459-62. PubMed ID: 21778401
[TBL] [Abstract][Full Text] [Related]
15. Design and synthesis of conformationally constrained hydroxylated 4-phenyl-2-aryl chromenopyridines as novel and selective topoisomerase II-targeted antiproliferative agents.
Thapa P; Jun KY; Kadayat TM; Park C; Zheng Z; Thapa Magar TB; Bist G; Shrestha A; Na Y; Kwon Y; Lee ES
Bioorg Med Chem; 2015 Oct; 23(19):6454-66. PubMed ID: 26361737
[TBL] [Abstract][Full Text] [Related]
16. Antitumor agents. 148. Synthesis and biological evaluation of novel 4 beta-amino derivatives of etoposide with better pharmacological profiles.
Zhang YL; Guo X; Cheng YC; Lee KH
J Med Chem; 1994 Feb; 37(4):446-52. PubMed ID: 8120864
[TBL] [Abstract][Full Text] [Related]
17. Coupling the core of the anticancer drug etoposide to an oligonucleotide induces topoisomerase II-mediated cleavage at specific DNA sequences.
Infante Lara L; Fenner S; Ratcliffe S; Isidro-Llobet A; Hann M; Bax B; Osheroff N
Nucleic Acids Res; 2018 Mar; 46(5):2218-2233. PubMed ID: 29447373
[TBL] [Abstract][Full Text] [Related]
18. Insight into eukaryotic topoisomerase II-inhibiting fused heterocyclic compounds in human cancer cell lines by molecular docking.
Taskin T; Yilmaz S; Yildiz I; Yalcin I; Aki E
SAR QSAR Environ Res; 2012; 23(3-4):345-55. PubMed ID: 22490049
[TBL] [Abstract][Full Text] [Related]
19. Design and synthesis of the novel DNA topoisomerase II inhibitors: esterification and amination substituted 4'-demethylepipodophyllotoxin derivates exhibiting anti-tumor activity by activating ATM/ATR signaling pathways.
Xiao L; Zhao W; Li HM; Wan DJ; Li DS; Chen T; Tang YJ
Eur J Med Chem; 2014 Jun; 80():267-77. PubMed ID: 24793877
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and Biological Activity of Ferrocenyl and Ruthenocenyl Analogues of Etoposide: Discovery of a Novel Dual Inhibitor of Topoisomerase II Activity and Tubulin Polymerization.
Chrabąszcz K; Błauż A; Gruchała M; Wachulec M; Rychlik B; Plażuk D
Chemistry; 2021 Apr; 27(20):6254-6262. PubMed ID: 33465263
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
